ADLARITY Drug Patent Profile
✉ Email this page to a colleague
When do Adlarity patents expire, and what generic alternatives are available?
Adlarity is a drug marketed by Corium and is included in one NDA. There are nine patents protecting this drug.
This drug has eighty-nine patent family members in eleven countries.
The generic ingredient in ADLARITY is donepezil hydrochloride. There are thirty-two drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adlarity
A generic version of ADLARITY was approved as donepezil hydrochloride by AUROBINDO on May 31st, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ADLARITY?
- What are the global sales for ADLARITY?
- What is Average Wholesale Price for ADLARITY?
Summary for ADLARITY
International Patents: | 89 |
US Patents: | 9 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 160 |
Patent Applications: | 4,015 |
Drug Prices: | Drug price information for ADLARITY |
What excipients (inactive ingredients) are in ADLARITY? | ADLARITY excipients list |
DailyMed Link: | ADLARITY at DailyMed |
Pharmacology for ADLARITY
Drug Class | Cholinesterase Inhibitor |
Mechanism of Action | Cholinesterase Inhibitors |
US Patents and Regulatory Information for ADLARITY
ADLARITY is protected by nine US patents and one FDA Regulatory Exclusivity.
Patents protecting ADLARITY
Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Donepezil transdermal delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Donepezil transdermal delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Systems and methods for long term transdermal administration
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Systems comprising a composite backing and methods for long term transdermal administration
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Methods for treating alzheimer's disease with donepezil transdermal system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Donepezil transdermal delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting ADLARITY
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-001 | Mar 11, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-002 | Mar 11, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-001 | Mar 11, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-001 | Mar 11, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-002 | Mar 11, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ADLARITY
See the table below for patents covering ADLARITY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2022087276 | メマンチン経皮送達システム | ⤷ Sign Up |
Mexico | 2018008190 | SISTEMAS Y METODOS PARA LA ADMINISTRACION TRANSDERMICA A LARGO PLAZO. (SYSTEMS AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION.) | ⤷ Sign Up |
South Korea | 20190034601 | 염 약물의 염 약물에서 중성 약물으로의 제자리 전환에 의한 저용해도 또는 불안정한 이온화되지 않은 중성 약물의 경피성 제제 및 전달 방법 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2018022818 | ⤷ Sign Up | |
South Korea | 102406528 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ADLARITY
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0296560 | SPC/GB97/023 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214 |
0296560 | 2/1998 | Austria | ⤷ Sign Up | PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |